Success for UCL start-up Autolus Therapeutics

The stock market success of the company Syncona is observed in an article describing its backing of Autolus Therapeutics, whose advanced cell programming technology was pioneered by Dr Martin Pule (UCL Cancer Institute).

Read: Times (£)